|
|
Clinical effect of Bushen Tongluo method combined with Alendronate Sodium in the treatment of ankylosing spondylitis with osteoporosis |
CHEN Nian |
The Second Department of Orthopaedics,Gaozhou Hospital of Traditional Chinese Medicine,Guangdong Province,Gaozhou 525200,China |
|
|
Abstract Objective To explore the clinical effect of Bushen Tongluo method combined with Alendronate Sodium in the treatment of ankylosing spondylitis with osteoporosis.Methods Eighty patients with ankylosing spondylitis (AS) and osteoporosis (OP) admitted to our hospital from August 2017 to June 2018 were selected and divided into the control group (40 cases) and the intervention group (40 cases) according to the random number table method.The control group was treated with Alendronate Sodium.The intervention group was treated combined with Bushen Tongluo method.The bone mineral density (BMD) of the lumbar vertebrae (L2-4),femoral neck and greater trochanter before and after treatment,bone-carboxyglutamate protein (BGP),procollagen type Ⅰamino-terminal prolonging peptide (PⅠNP),carboxyterminal telopeptide of type Ⅰcollagen (CTX) content were compared between the two groups,and the total clinical effectiveness after treatment was observed.Results After treatment,the BMD of L2-4,femoral neck and greater trochanter were higher than those before treatment.The BGP and PⅠNP levels of the two groups were higher than those before treatment,and the CTX level was lower than that before treatment.The BMD of L2-4,femoral neck and greater trochanter of the intervention group were higher than those of the control group.The BGP and PⅠNP levels in the intervention group were higher than those in the control group,and the CTX level was lower than that in the control group,the differences were statistically significant (P<0.05).The total effective rate of the intervention group was 92.50%,which was higher than that of the control group (75.00%),and the difference was statistically significant (P<0.05).Conclusion The combination of Bushen Tongluo method and Alendronate Sodiumin in the treatment of patients with AS and OP can significantly improve clinical efficacy and improve bone metabolism and BMD.
|
|
|
|
|
[4] |
白璧辉,谢兴文,李鼎鹏,等.我国近5年来骨质疏松症流行病学研究现状[J].中国骨质疏松杂志,2018,24(2):253-258.
|
[5] |
文利,王国良,蒋薇,等.阿仑磷酸钠对男性强直性脊柱炎伴骨质疏松患者骨代谢及骨密度的影响[J].中国乡村医药,2017,24(5):23-24.
|
[1] |
Nhan DT,Caplan L.Patient-reported outcomes in axial spondyloarthritis[J].Rheum Dis Clin North Am,2016,42(2):285-299.
|
[2] |
韩仁芳,陈梦雅,刘瑞,等.强直性脊柱炎2261 例流行特征及功能状态现状分析[J].安徽医药,2017,21(1):73-76.
|
[3] |
卢洋,孙术宁,陈国铭,等.灸法治疗强直性脊柱炎临床疗效的Meta 分析[J].上海针灸杂志,2018,37(5):98-104.
|
[6] |
徐子琦,刘宏潇,高凡珠,等.对清热利湿法治疗活动期强直性脊柱炎的认识[J].中医杂志,2017,58(20):1793-1795.
|
[7] |
杨燕,刘仁慧,王秀娟.中药治疗糖皮质激素性骨质疏松症的药理研究进展[J].北京中医药,2016,35(3):275-278.
|
[8] |
李文成.强直性脊柱炎骶髂关节病变患者应用MRI 与MSCT 的诊断效果比较[J].中国疗养医学,2018,27(4):392-393.
|
[9] |
中华骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松与骨矿盐疾病杂志,2011,4(1):2.
|
[10] |
国家食品药品监督管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:116.
|
[11] |
Wang DM,Zeng QY,Chen SB,et a l.Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis:a 5-year follow-up study of 504 cases[J].Clin Exp Rheumatol,2015,33(4):465-470.
|
[12] |
李瑞琦,张国平,李宜炯,等.强直性脊柱炎患者并发骨质疏松及其骨密度和骨代谢生化指标变化情况[J].中国全科医学,2014,17(9):1049-1051.
|
[13] |
康日辉,陈君敏,郑玲,等.强直性脊柱炎患者骨密度及骨代谢标志物的变化[J].中国骨质疏松杂志,2016,22(1):61-66.
|
[14] |
周建江,卫四来.中医药治疗原发性骨质疏松症研究进展[J].辽宁中医药大学学报,2014,16(7):246-248.
|
[15] |
侯喆,刘瑞霞.狗脊配伍及现代应用[J].内蒙古中医药,2017,36(19):137-138.
|
|
|
|